XML 14 R7.htm IDEA: XBRL DOCUMENT v3.26.1
Condensed Consolidated Statements of Cash Flows (Unaudited) - USD ($)
$ in Thousands
 6 Months Ended
Jun. 30, 2026
Jun. 30, 2025
Operating activities    
Net loss $ (59,956) $ (55,423)
Adjustments to reconcile net loss to net cash used in operating activities    
Depreciation expense 6,690 8,391
Noncash lease expense 2,574 2,642
Share-based compensation expense 23,047 25,506
Intangible assets amortization 842 842
Investment amortization (248) (1,708)
Impairment of long-lived assets 347 0
Write-off of inventory 2 (46)
Revenue interest purchase agreement and convertible senior notes interest (6,789) 287
Loss on revenue interest liability extinguishment 23,733 0
Other (106) 43
Changes in operating assets and liabilities    
Accounts receivable, net 852 (2,566)
Inventory (754) 359
Prepaid expenses and other current assets (2,526) (8)
Accounts payable and accrued liabilities (6,502) (6,396)
Operating lease right-of-use assets and liabilities (4,605) (5,230)
Deferred revenue 7,663 (7,612)
Other (201) 5
Net cash used in operating activities (15,937) (40,914)
Investing activities    
Purchases of property and equipment (1,980) (1,914)
Purchases of marketable securities (121,588) (101,792)
Proceeds from maturities of marketable securities 89,234 132,625
Net cash (used in) provided by investing activities (34,334) 28,919
Financing activities    
Proceeds from exercise of stock options 10,407 7,061
Proceeds from capital contributions for Digital Biotechnologies, Inc. 2,475 0
Revenue interest liability extinguishment (148,108) 0
Proceeds from convertible senior notes, net of issuance costs 335,513 0
Repurchase of common stock (25,000) 0
Purchase of capped calls (25,599) 0
Net cash provided by financing activities 149,688 7,061
Net increase (decrease) in cash, cash equivalents and restricted cash 99,417 (4,934)
Cash, cash equivalents and restricted cash at beginning of year 73,184 50,817
Cash, cash equivalents and restricted cash at end of period 172,601 45,883
Noncash investing and financing activities    
Purchases of equipment included in accounts payable and accrued liabilities 806 224
Convertible senior notes issuance costs included in accounts payable and accrued liabilities 680 0
Supplemental disclosure of cash flow information    
Cash paid for interest 15,957 4,995
Reconciliation of cash, cash equivalents and restricted cash at end of period    
Cash and cash equivalents at end of period 169,873 43,163
Restricted cash at end of period 2,728 2,720
Total cash, cash equivalents and restricted cash at end of period $ 172,601 $ 45,883